OKYO Pharma Secures $1.4M Non-Dilutive Funding
Ticker: OKYO · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.4 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: funding, pipeline, non-dilutive
TL;DR
OKYO Pharma just got $1.4M non-dilutive funding to advance pipeline - no new shares issued!
AI Summary
On January 22, 2025, OKYO Pharma Ltd announced it has secured $1.4 million in non-dilutive funding. This capital infusion will support the advancement of the company's pipeline without issuing new shares, thus preserving shareholder value.
Why It Matters
This funding allows OKYO Pharma to progress its drug development pipeline without diluting existing shareholders, potentially leading to future value creation.
Risk Assessment
Risk Level: low — The filing is a routine announcement of funding and does not contain significant negative news or operational changes.
Key Numbers
- $1.4M — Non-dilutive funding (Strengthens company's ability to advance pipeline without diluting shareholders.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Company filing the report
- $1.4 million (dollar_amount) — Amount of non-dilutive funding received
- January 22, 2025 (date) — Date of the announcement
FAQ
What is the source of the $1.4 million funding?
The filing states the funding is 'non-dilutive' but does not specify the source.
How will the $1.4 million be specifically allocated?
The filing indicates the funds will be used to 'advance its innovative pipeline' but does not provide specific allocation details.
What is OKYO Pharma's principal executive office address?
OKYO Pharma's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
When was this Form 6-K filed?
This Form 6-K was filed on January 22, 2025.
Does OKYO Pharma file annual reports on Form 20-F or 40-F?
OKYO Pharma indicates it files annual reports under cover of Form 20-F.
Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 14.3 · Accepted 2025-01-22 07:00:26
Key Financial Figures
- $1.4 million — announcing today, that it has received $1.4 million in non-dilutive funding. This significa
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001493152-25-003148.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: January 22, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Announcement, dated Janaury 22, 2025 4